(R)-(-)-N-(3-phenyl-1-propyl)-1-phenyl-2-aminopropane | 132017-86-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (R)-(-)-N-(3-phenyl-1-propyl)-1-phenyl-2-aminopropane
• 英文别名: ((R)-1-Methyl-2-phenyl-ethyl)-(3-phenyl-propyl)-amine；(2R)-1-phenyl-N-(3-phenylpropyl)propan-2-amine
• CAS: 132017-86-8
• 化学式: C₁₈H₂₃N
• 分子量: 253.387
• InChiKey: CYWPIEBWQAZHQX-MRXNPFEDSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.5
• 重原子数：
  19
• 可旋转键数：
  7
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  12
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  (R)-(-)-N-(3-phenyl-1-propyl)-1-phenyl-2-aminopropane 、 碘甲烷 反应 20.0h， 以34%的产率得到(R)-(-)-N-methyl-(1-methyl-2-phenylethyl)-3-phenyl-1-aminopropane methiodide
  参考文献：
  名称：

  Structural Features Important for .sigma.1 Receptor Binding

  摘要：

  Two problems that have hampered a receptor research are (i) a lack of high-affinity agents and iii) the recent identification Of multiple populations of a receptors (i.e., sigma(1) and sigma(2) sites). Recently, several high-affinity sigma ligands have been identified, and the term superpotent sigma ligands has been coined to describe agents with K-i values of <1 nM. We have previously shown that appropriately N-substituted phenylalkylamines bind at a receptors with high affinity. In the present investigation, we examine the structure-affinity relationships of these phenylalkylamine derivatives for sigma binding and describe some of the first superpotent sigma(1) ligands. A binding model was developed to account for the structural features of the phenylalkylamines that appear to be important for the interaction of these agents with sigma(1) sites.

  DOI：

  10.1021/jm00034a020
• 作为产物：
  描述：

  苯丙醛 、 左苯丙胺 在 platinum on activated charcoal 氢气 作用下， 以 甲醇 为溶剂， 生成 (R)-(-)-N-(3-phenyl-1-propyl)-1-phenyl-2-aminopropane
  参考文献：
  名称：

  Identification and exploitation of the .sigma.-opiate pharmacophore

  摘要：

  Certain benzomorphan ''sigma-opiates'' such as N-allylnormetazocine (NANM) bind at sigma receptors with modest affinity and with little selectivity (i.e., they also bind at phencyclidine or PCP sites). In order to identify the primary pharmacophore of the benzomorphans, we prepared several amine-substituted derivatives of 1-phenyl-2-aminopropane. Several simple alkyl-substituted analogues were shown to bind at sigma sites with affinities comparable to that of NANM itself; among these was the N-benzyl derivative 9 (K(i) = 117 nM). Lengthening the spacer between the terminal amine and the phenyl group from one to five methylene units resulted in a significant increase in affinity (e.g. 15, K(i) = 6.3 nM). In addition, unlike the benzomorphans, these phenalkylamines do not bind at PCP sites. The results of the present study reveal that (a) the 1-phenyl-2-aminopropane nucleus of the benzomorphans is sufficient for binding at sigma sites provided that the terminal amine is not a primary amine and that (b) introduction of (phenylalkyl)amine substituents affords compounds that represent a new class of high-affinity sigma-selective agents.

  DOI：

  10.1021/jm00107a033

文献信息

• Muscarinic receptor antagonists
  申请人：Aggen James

  公开号：US20090306134A1

  公开（公告）日：2009-12-10

  Disclosed are multibinding compounds which are muscarinic receptor antagonists. The multibinding compounds of this invention containing from 2 to 10 ligands covalently attached to one or more linkers. Each ligand is, independently of each other, a muscarinic receptor antagonist or an allosteric modulator provided that at least one of said ligand is a muscarinic receptor antagonist. The multibinding compounds of this invention are useful in the treatment and prevention of diseases such as chronic obstructive pulmonary disease, chronic bronchitis, irritable bowel syndrome, urinary incontinence, and the like.

  本发明涉及一种多结合化合物，其为肌动蛋白受体拮抗剂。该发明的多结合化合物包含2至10个配体共价连接到一个或多个连接体上。每个配体是独立的，可以是肌动蛋白受体拮抗剂或变构调节剂，但至少其中一个配体是肌动蛋白受体拮抗剂。本发明的多结合化合物在治疗和预防慢性阻塞性肺疾病、慢性支气管炎、肠易激综合征、尿失禁等疾病方面具有用途。
• Vesicular monoamine transporter-2 ligands and their use in the treatment of psychostimulant abuse
  申请人：University of Kentucky Research Foundation

  公开号：US10668030B2

  公开（公告）日：2020-06-02

  The present invention relates to methods of treatment of a disease or pathology of the central nervous system, an eating disorder, or substance use disorder, drug dependence/abuse and withdrawal therefrom comprising administering at least one N-phenylalkyl amphetamine derivative and pharmaceutical compositions comprising at least one N-phenylalkyl amphetamine derivative to an individual in need thereof.

  本发明涉及治疗中枢神经系统疾病或病理、饮食失调或药物使用失调、药物依赖/滥用及其戒断的方法，包括向有需要的个体施用至少一种N-苯基烷基苯丙胺衍生物和包含至少一种N-苯基烷基苯丙胺衍生物的药物组合物。
• VESICULAR MONOAMINE TRANSPORTER-2 LIGANDS AND THEIR USE IN THE TREATMENT OF PSYCHOSTIMULANT ABUSE
  申请人：University of Kentucky Research Foundation

  公开号：US20200237688A1

  公开（公告）日：2020-07-30

  The present invention relates to methods of treatment of a disease or pathology of the central nervous system, an eating disorder, or substance use disorder, drug dependence/abuse and withdrawal therefrom comprising administering at least one N-phenylalkyl amphetamine derivative and pharmaceutical compositions comprising at least one N-phenylalkyl amphetamine derivative to an individual in need thereof.
• Vesicular Monoamine Transporter-2 Ligands and Their Use in the Treatment of Psychostimulant Abuse
  申请人：University of Kentucky Research Foundation

  公开号：US20200290948A1

  公开（公告）日：2020-09-17

  The present invention relates to methods of treatment of a disease or pathology of the central nervous system, an eating disorder, or substance use disorder, drug dependence/abuse and withdrawal therefrom comprising administering at least one N-phenylalkyl amphetamine derivative and pharmaceutical compositions comprising at least one N-phenylalkyl amphetamine derivative to an individual in need thereof.
• US7238709B2
  申请人：——

  公开号：US7238709B2

  公开（公告）日：2007-07-03